榴莲视频

Endocrinology >

Metabolic Syndrome

News, opinions and meeting coverage in endocrinology.

ESC: Xarelto Safe for Cardioverting Afib

BARCELONA -- Switching atrial fibrillation patients awaiting elective cardioversion to rivaroxaban (Xarelto) was as safe as warfarin in that setting.

Do Fat Teens Face an Early Death?

Life expectancy gains seen over the last half-century do not appear to extend to adults who were overweight or obese in adolescence, according to a large study spanning several decades.

How Much Exercise to Burn Off a Burger?

Menus displaying the amount of exercise required to burn off calories in a meal had some impact on food choice, researchers found.

Cardio Notes: Sex Improves with Stenting

Opening the arteries of those with stable coronary disease also opens the door to an improved sex life. Also this week, bariatric surgery helps remodel the heart.

Doctors Say 45 Common Tests 'Overused'

Nine specialty groups have listed tests and treatments that are frequently overused, such as antibiotics for sinus attacks and CT scans for low back pain, in the first phase of a long-term project.

FDA Adds More Warnings for Lipitor, Crestor, and Zocor

WASHINGTON -- Statins may cause drug-drug interactions for patients taking drugs to treat HIV/AIDS or hepatitis C, according to a new statin warning from the FDA.

FDA Adds Diabetes Warning to Statin Label

WASHINGTON -- The FDA is changing the labeling on statins to include a warning about increased risks of hyperglycemia and transient memory problems, but the agency is no longer recommending routine liver function testing.

Fructose No Substitute for Glucose in Diabetes

NEW YORK -- Although it negates the dumping of glucose directly into the bloodstream, fructose may not be the choice sweetener for diabetics, researchers said here.

ACC: Triglycerides Decreased with Rosuvastatin Therapy

ATLANTA -- In a study that specifically scrutinized the effects of statin therapy on triglycerides, researchers said that rosuvastatin (Crestor) significantly reduced the blood lipid that has been linked to coronary artery disease better than placebo.

ACC: FDA Announces Review of ACCORD Data

ATLANTA -- The FDA said it will conduct a full review of findings from a study which concluded that neither aggressive lipid-lowering therapy nor tight blood pressure control reduced cardiovascular events in persons with diabetes.

Normal Enzyme Levels May Hide Advanced Liver Fibrosis

MILAN, Italy -- Patients with nonalcoholic fatty liver disease but normal alanine aminotransferase (ALT) levels are still at risk of severe hepatic disease, researchers found.